Marie‐Laure Risse

1.5k total citations
41 papers, 725 citations indexed

About

Marie‐Laure Risse is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Marie‐Laure Risse has authored 41 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 24 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Marie‐Laure Risse's work include Multiple Myeloma Research and Treatments (34 papers), Peptidase Inhibition and Analysis (15 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Marie‐Laure Risse is often cited by papers focused on Multiple Myeloma Research and Treatments (34 papers), Peptidase Inhibition and Analysis (15 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Marie‐Laure Risse collaborates with scholars based in France, United States and Czechia. Marie‐Laure Risse's co-authors include F Pein, Alexandre Santos, Gilles Vassal, Philippe Moreau, Éric Raymond, Alain Deroussent, Alain Gouyette, Laurent Vernillet, Thierry Cresteil and Sylvie Zanetta and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Marie‐Laure Risse

39 papers receiving 708 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marie‐Laure Risse France	12	487	421	308	129	68	41	725
Timothy M. Lestingi United States	11	560 1.1×	599 1.4×	48 0.2×	179 1.4×	35 0.5×	26	844
Shelley Orwick United States	22	496 1.0×	613 1.5×	820 2.7×	111 0.9×	31 0.5×	60	1.5k
François Wilhelm United States	16	264 0.5×	270 0.6×	220 0.7×	67 0.5×	173 2.5×	64	796
M. Ravic United Kingdom	14	398 0.8×	299 0.7×	57 0.2×	92 0.7×	222 3.3×	36	973
Mark Wong Australia	14	393 0.8×	123 0.3×	64 0.2×	126 1.0×	60 0.9×	27	658
C.J. Bol Netherlands	8	391 0.8×	271 0.6×	61 0.2×	87 0.7×	41 0.6×	10	557
Devron R. Shah United Kingdom	7	241 0.5×	190 0.5×	95 0.3×	187 1.4×	30 0.4×	8	599
J. A. Ware United States	10	218 0.4×	317 0.8×	61 0.2×	215 1.7×	42 0.6×	23	599
Lavina Bharwani Singapore	9	491 1.0×	356 0.8×	61 0.2×	179 1.4×	20 0.3×	13	861
Amy de Haar-Holleman Netherlands	8	188 0.4×	679 1.6×	235 0.8×	41 0.3×	25 0.4×	14	1.1k

Countries citing papers authored by Marie‐Laure Risse

Since Specialization

Citations

This map shows the geographic impact of Marie‐Laure Risse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie‐Laure Risse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie‐Laure Risse more than expected).

Fields of papers citing papers by Marie‐Laure Risse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie‐Laure Risse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie‐Laure Risse. The network helps show where Marie‐Laure Risse may publish in the future.

Co-authorship network of co-authors of Marie‐Laure Risse

This figure shows the co-authorship network connecting the top 25 collaborators of Marie‐Laure Risse. A scholar is included among the top collaborators of Marie‐Laure Risse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie‐Laure Risse. Marie‐Laure Risse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Façon, Thierry, Philippe Moreau, Ivan Špıčka, et al.. (2024). Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study. Hematological Oncology. 42(2). 6 indexed citations

Façon, Thierry, Philippe Moreau, Ross Baker, et al.. (2023). Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis. Haematologica. 109(2). 604–616. 11 indexed citations

Kawano, Yawara, Kihyun Kım, Chang Ki Min, et al.. (2023). Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis. Clinical Lymphoma Myeloma & Leukemia. 23(10). e360–e367.

Façon, Thierry, Philippe Moreau, Ivan Špıčka, et al.. (2023). Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study.. Journal of Clinical Oncology. 41(16_suppl). 8029–8029. 2 indexed citations

Rodriguez, Cesar, Aurore Perrot, Paul G. Richardson, et al.. (2023). The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 142(Supplement 1). 1980–1980. 3 indexed citations

Kım, Kihyun, Chang‐Ki Min, Youngil Koh, et al.. (2022). Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. International Journal of Hematology. 116(4). 553–562. 3 indexed citations

Martin, Thomas G., Marcelo Capra, Mohamad Mohty, et al.. (2022). Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. Transplantation and Cellular Therapy. 29(2). 134.e1–134.e7. 2 indexed citations

Ishida, Tadao, Shigeki Ito, Junji Tanaka, et al.. (2022). Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study. Japanese Journal of Clinical Oncology. 52(12). 1446–1449. 1 indexed citations

Martin, Thomas G., Meletios Α. Dimopoulos, Joseph Mıkhael, et al.. (2022). MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 22. S403–S404. 1 indexed citations

10.

Martin, Thomas G., Joseph Mıkhael, Roman Hájek, et al.. (2022). Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Advances. 6(15). 4506–4515. 6 indexed citations

11.

Martin, Thomas G., Marcelo Capra, Mohamad Mohty, et al.. (2021). Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S65–S65. 2 indexed citations

12.

Harrison, Simon J., Aurore Perrot, Adrían Alegre, et al.. (2021). Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics. British Journal of Haematology. 194(1). 120–131. 32 indexed citations

13.

Capra, Marcelo, Thomas G. Martin, Philippe Moreau, et al.. (2021). Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. Haematologica. 107(6). 1397–1409. 19 indexed citations

14.

Façon, Thierry, Philippe Moreau, Thomas Martin, et al.. (2021). Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.. Journal of Clinical Oncology. 39(15_suppl). 8026–8026. 7 indexed citations

15.

Martin, Thomas G., Joseph Mıkhael, Roman Hájek, et al.. (2020). Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. Blood. 136(Supplement 1). 7–8. 12 indexed citations

16.

Maiolino, Ângelo, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2020). ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY. Hematology Transfusion and Cell Therapy. 42. 262–263. 23 indexed citations

17.

Turgut, Mehmet, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2020). Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study. Hematology Transfusion and Cell Therapy. 42. 51–52. 6 indexed citations

18.

Martin, Thomas G., Meletios Α. Dimopoulos, Kwee Yong, et al.. (2018). Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 36(15_suppl). TPS8060–TPS8060. 2 indexed citations

19.

Sternberg, Cora N., Iwona Skoneczna, Daniel Castellano, et al.. (2013). Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB). Oncology. 85(4). 208–215. 30 indexed citations

20.

Santos, Alexandre, Sylvie Zanetta, Thierry Cresteil, et al.. (2000). Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.. PubMed. 6(5). 2012–20. 178 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact